The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

MLA

Spellberg B, et al. “The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial.” Journal of Antimicrobial Chemotherapy (JAC), vol. 67, no. 3, Mar. 2012, pp. 715–22. EBSCOhost, https://doi.org/10.1093/jac/dkr375.

APA

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP, Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012). The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. Journal of Antimicrobial Chemotherapy (JAC), 67(3), 715–722. https://doi.org/10.1093/jac/dkr375

Chicago

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, et al. 2012. “The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial.” Journal of Antimicrobial Chemotherapy (JAC) 67 (3): 715–22. doi:10.1093/jac/dkr375.